Neurobiology of Aging
Volume 30, Issue 7 , Pages 1011-1025 , July 2009

Neurodegeneration and peroxidases

Received 18 July 2007 ,Revised 21 September 2007 ,Accepted 13 October 2007.

References 

  1. Agil A, Duran R, Barrero F, Morales B, Arauzo M, Alba F, et al. Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the l-dopa. J. Neurol. Sci. 2006;240:31–36
  2. Akama KT, Albanese C, Pestell RG, Van Eldik LJ. Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NkκB-dependent mechanism. Proc. Natl. Acad. Sci. U.S.A. 1998;95:5795–5800
  3. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc. Natl. Acad. Sci. U.S.A. 2006;103:9685–9690
  4. Arnhold J, Furtmüller PG, Regelsberger G, Obinger C. Redox properties of the couple compound I/native enzyme of myeloperoxidase and eosinophil peroxidase. Eur. J. Biochem. 2001;268:5124–5148
  5. Arnhold J, Furtmüller PG, Obinger C. Redox properties of myeloperoxidase. Redox Rep. 2003;8:179–186
  6. Atamna H. Heme binding to amyloid-beta peptide: mechanistic role in Alzheimer's disease. J. Alzheimers Dis. 2006;10:255–266
  7. Atamna H, Boyle K. Amyloid-β peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2006;103:3381–3386
  8. Aubin N, Curet O, Deffois A, Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J. Neurochem. 1998;71:1635–1642
  9. Bains JS, Shaw CA. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Brain Res. Rev. 1997;25:335–358
  10. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology. 1985;35:949–956
  11. Barcia C, Sanchez Bahillo A, Fernandez-Villalba E, Bautista V, Poza Y, Poza M, et al. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia. 2004;46:402–409
  12. Barone FC, Hillegass LM, Price WJ, White RF, Lee EV, Feuerstein GZ, et al. Polymorphonuclear leukocyte infiltration into cerebral focal ischemic tissue: myeloperoxidase activity assay and histologic verification. J. Neurosci. Res. 1991;29:336–345
  13. Bartov O, Sultana R, Butterfield DA, Atlas D. Low molecular weight thiol amides attenuate MAPK activity and protect primary neurons from Abeta(1-42) toxicity. Brain Res. 2006;1069:198–206
  14. Batthyany C, Souza JM, Duran R, Cassina A, Cervenansky C, Radi R. Time course and site(s) of cytochrome c tyrosine nitration by peroxynitrite. Biochemistry. 2005;44:8038–8046
  15. Beal F, Lang A. The proteasomal inhibition model of Parkinson's disease: “Boon or bust”?. Ann. Neurol. 2006;60:158–161
  16. Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 2005;58:495–505
  17. Beckman JS, Crow JP. Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochem. Soc. Trans. 1993;21:330–334
  18. Belikova NA, Vladimirov YA, Osipov AN, Kapralov AA, Tyurin VA, Potapovich MV, et al. Peroxidase activity and, structural transitions of cytochrome c bound to cardiolipin-containing membranes. Biochemistry. 2006;45:4998–5009
  19. Ben-Shachar D, Eshel G, Finberg JPM, Youdim MBH. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 1991;56:1441–1444
  20. Bernardo A, Gasparini L, Ongini E, Minghetti L. Dynamic regulation of microglial functions by the non-steroidal anti-inflammatory drug NCX 2216: implications for chronic treatments of neurodegenerative diseases. Neurobiol. Dis. 2005;22:25–32
  21. Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M. Clinical potential of minocycline for neurodegenerative disorders. Neurobiol. Dis. 2004;17:359–366
  22. Bobba A, Atlante A, Giannattasio S, Sgaramella G, Calissano P, Marra E. Early release and subsequent caspase-mediated degradation of cytochrome c in apoptotic cerebellar granule cells. FEBS Lett. 1999;457:126–130
  23. Bogdanov MB, Ramos LE, Xu Z, Beal MF. Elevated “hydroxyl radical” generation in vivo in an animal model of amyotrophic lateral sclerosis. J. Neurochem. 1998;71:1321–1324
  24. Bonini MG, Radi R, Ferrer-Sueta G, Ferreira AM, Augusto O. Direct EPR detection of the carbonate radical anion produced from peroxynitrite and carbon dioxide. J. Biol. Chem. 1999;274:10806–19802
  25. Bonini MG, Fernandes DC, Augusto O. Albumin oxidation to diverse radicals by the peroxidase activity of Cu-Zn-superoxide dismutase in the presence of bicarbonate or nitrite: diffusible radicals produce cysteinyl and solvent-exposed and -unexposed tyrosyl radicals. Biochemistry. 2004;43:344–351
  26. Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 2004;27:723–749
  27. Burkitt M, Jones C, Lawrence A, Wardman P. Activation of cytochrome c to a peroxidase compound I-type intermediate by H2O2: relevance to redox signalling in apoptosis. Biochem. Soc. Symp. 2004;71:97–106
  28. Burns RS, LeWitt PA, Ebert MH, Pakkenberg H, Kopin IJ. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). New Engl. J. Med. 1985;312:1418–1421
  29. Casoni F, Basso M, Massignan T, Gianazza E, Cheroni C, Salmona M, et al. Protein nitration in a mouse model of familial amyotrophic lateral sclerosis: possible multifunctional role in the pathogenesis. J. Biol. Chem. 2005;280:16295–16304
  30. Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, et al. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 2005;19:2040–2041
  31. Cassina AM, Hodara R, Souza JM, Thomson L, Castro L, Ischiropoulos H, et al. Cytochrome c nitration by peroxynitrite. J. Biol. Chem. 2000;275:21409–21415
  32. Castro L, Eiserich JP, Sweeney S, Radi R, Freeman BA. Cytochrome c: a catalyst and target of nitrite-hydrogen peroxide-dependent protein nitration. Arch. Biochem. Biophys. 2004;421:99–107
  33. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin L-S, et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 2004;279:13256–13264
  34. Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, Li L. Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J. Biol. Chem. 2005;280:11648–11655
  35. Choi D-K, Pennathur S, Perier C, Tieu K, Teismann P, Wu D-C, et al. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J. Neurosci. 2005;25:6594–6600
  36. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 1998;64:573–576
  37. Coma M, Guix FX, Uribesalgo I, Espuna G, Sole M, Andreu D, et al. Lack of oestrogen protection in amyloid-mediated endothelial damage due to protein nitrotyrosination. Brain. 2005;128:1613–1621
  38. Combs SH, Morgan CD, Everse J. Antitumor activity of an immobilized peroxidase system against murine Ehrlich ascites is mediated by the immune system. Proc. Soc. Exp. Biol. Med. 1993;204:306–311
  39. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1979;1:249–254
  40. Date I, Felten DL, Felten SY. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Res. 1990;519:266–276
  41. Denicola A, Souza JM, Radi R. Diffusion of peroxynitrite across erythrocyte membranes. Proc. Natl. Acad. Sci. U.S.A. 1998;95:3566–3571
  42. Drachman DB, Frank K, Dykes-Hoberg M, Teismann P, Almer G, Przedborski S, et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 2002;52:771–778
  43. Eidelberg E, Brooks BA, Morgan WW, Walden JG, Kokemoor RH. Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys. Neuroscience. 1986;18:817–822
  44. Everse J. The structure of heme proteins Compounds I and II: some misconceptions. Free Radic. Biol. Med. 1998;24:1338–1346
  45. Everse J, Coates PW. The cytotoxic activity of lactoperoxidase: enhancement and inhibition by neuroactive compounds. Free Radic. Biol. Med. 2004;37:839–849
  46. Everse J, Coates PW. Role of peroxidases in Parkinson's disease: a hypothesis. Free Radic. Biol. Med. 2005;38:1296–1310
  47. Everse J, Ginsburgh CL, Kaplan NO. Immobilized enzymes in biochemical analysis. In:  Glick D editors. Methods of Biochemical Analysis. vol. 25:New York: John Wiley and Sons; 1979;p. 136–201
  48. Everse J, Johnson MC, Marini MA. Peroxidative activities of hemoglobin and hemoglobin derivatives. In:  Everse J,  Vandegriff KD,  Winslow RM editor. Hemoglobins; Biochemical and Analytical Methods (Methods in Enzymology). vol. 231:San Diego: Academic Press; 1994;p. 547–561
  49. Everse KE, Lin H, Stuyt EL, Brady JC, Buddingh F, Everse J. Antitumour activity of peroxidases. Br. J. Cancer. 1985;51:743–746
  50. Familian A, Boshuizen RS, Eikelenboom P, Veerhuis R. Inhibitory effect of minocycline on amyloid beta fibril formation and human microglial activation. Glia. 2006;53:233–240
  51. Fiskum G, Starkov A, Polster BM, Chinopoulos C. Micochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson's disease. Ann. N Y Acad. Sci. 2003;991:111–119
  52. Forno LS, DeLanney LE, Irwin I, Langston JW. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease. Neuropathologic considerations. Adv. Neurol. 1993;60:600–608
  53. Gao H-M, Liu B, Zhang W, Hong J-S. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J. 2003;17:1954–1956
  54. Garcia-Allano, M., Borrelli, L.A., Rozkalne, A., Hyman, B.T., Bacskai, B.J., 2007. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alkzheimer mouse model. J. Neurochem. doi:10.1111/j.1471-4159.2007.04613.x.
  55. Giovannini MG, Scali C, Prosperi C, Bellucci A, Pepeu G, Casamenti F. Experimental brain inflammation and neurodegeneration as model of Alzheimer's disease: protective effects of selective COX-2 inhibitors. Int. J. Immunopathol. Pharmacol. 2003;16(2 Suppl.):31–40
  56. Goldstein S, Czapski G. Reactivity of peroxynitrite versus simultaneous generation of NO and O2− toward NADH. Chem. Res. Toxicol. 2000;13:736–741
  57. Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence of neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol. 1996;149:21–28
  58. Green PS, Mendez AJ, Jacobs JS, Crowley JR, Growdon W, Hyman BT, et al. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J. Neurochem. 2004;90:724–733
  59. Grisham MB, Perez VJ, Everse J. Neuromelanogenic and cytotoxic properties of canine brainstem peroxidase. J. Neurochem. 1987;48:876–882
  60. Guegan C, Vila M, Rosoklija G, Hays AP, Przedborski S. Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J. Neurosci. 2001;21:6569–6576
  61. Gunther MR, Hsi LC, Curtis JF, Gierse JK, Marnett LJ, Eling TE, et al. Nitric oxide trapping of the tyrosyl radical of prostaglandin H synthase-2 leads to tyrosine iminoxyl radical and nitrotyrosine formation. J. Biol. Chem. 1997;272:17086–17090
  62. Gurney ME. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J. Neurol. Sci. 1997;152:S67–S73
  63. Hasegawa E, Takeshige K, Oishi T, Murai Y, Minakami S. MPP+ induces NADH dependent superoxide formation and enhances NADH dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun. 1990;170:1049–1055
  64. Hashimoto M, Takeda A, Hsu LJ, Takenouchi T, Masliah E. Role of cytochrome c as a stimulator of α -synuclein aggregation in Lewy body disease. J. Biol. Chem. 1999;274:28849–28852
  65. Heidenreich KA. Molecular mechanisms of neuronal cell death. Ann. N Y Acad. Sci. 2003;991:237–250
  66. Henderson WR. Eosinophil peroxidase: occurrence and biological function. In:  Everse J,  Everse KE,  Grisham MB editor. Peroxidases in Chemistry and Biology. vol. 1:Boca Raton: CRC Press; 1991;p. 105–121
  67. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP. The role of glial reaction and inflammation in Parkinson's disease. Ann. N Y Acad. Sci. 2003;991:214–228
  68. Hoozemans JJM, Rozemuller AJM, Janssen I, De Groot CJA, Veerhuis R, Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol. 2001;101:2–8
  69. Hoozemans JJ, Bruckner MK, Rozemuller AJ, Veerhuis R, Eikelenboom P, Arendt T. Cyclin D1 and cyclin E are co-localized with cyclooxygenase 2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex. J. Neuropathol. Exp. Neurol. 2002;61:678–688
  70. Huber A, Stuchbury G, Burkle A, Burnell J, Munch G. Neuroprotective therapies for Alzheimer's disease. Curr. Pharm. Des. 2006;12:705–717
  71. Jang B, Han S. Biochemical properties of cytochrome c nitrated by peroxynitrite. Biochimie. 2006;88:53–58
  72. Jiang J, Serinkan BF, Tyurina AA, Borisenko GG, Mi Z, Robbins PD, et al. Peroxidation and externalization of phosphatidylserine associated with release of cytochrome c from mitochondria. Free Radic. Biol. Med. 2003;35:814–825
  73. Johannessen JN, Chiueh CC, Burns RS, Markey SP. Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effect. Life Sci. 1985;36:219–224
  74. Johnston JA, Dalton MJ, Gurney ME, Kopito RR. Formation of high molecular weight complexes of mutant Cu-Zn superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A. 2000;97:12571–12576
  75. Jolivalt C, Leininger-Muller B, Drozdz R, Naskalski JW, Siest G. Apolipoprotein E is highly susceptible to oxidation by myeloperoxidase, an enzyme present in the brain. Neurosci. Lett. 1996;210:61–64
  76. Jordan J, Cena V, Prehn JH. Mitochondrial control of neuron death and its role in neurodegenerative disorders. J. Physiol. Biochem. 2003;59:129–141
  77. Kagan VE, Tyurina YY, Bayir H, Chu CT, Kapralov AA, Vlasova II, et al. The “pro-apoptotoc genies” get out of mitochondria: oxidative lipidomics and redox activity of cytochrome c/cardiolipin complexes. Chem. Biol. Interact. 2006;163:15–28
  78. Kang JH, Eum WS. Enhanced oxidative damage by the familial amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutants. Biochim. Biophys. Acta. 2000;1524:162–170
  79. Kirkinezos IG, Bacman SR, Hernandez D, Oca-Cossio J, Arias LJ, Perez-Pinzon MA, et al. Cytochrome c association with the inner mitochondrial membrane is impaired in the CNS of G93A-SOD1 mice. J. Neurosci. 2005;25:164–172
  80. Klebanoff SJ. Myeloperoxidase: occurrence and biological function. In:  Everse J,  Everse KE,  Grisham MB editor. Peroxidases in Chemistry and Biology. vol. 1:Boca Raton: CRC Press; 1991;p. 1–35
  81. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, et al. Neuroprotective effects of creatine in a transgenic animal model of amylotrophic lateral sclerosis. Nat. Med. 1999;5:347–350
  82. Kordower JH, Kanaan NM, Chu Y, Suresh Babu R, Stansell J, Terpstra BT, et al. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann. Neurol. 2006;60:264–268
  83. Kostic V, Jackson-Lewis V, De Bilbao F, Dubois-Dauphin M, Przedborski S. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science. 1997;277:559–562
  84. Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2002;10:268–278
  85. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979–980
  86. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 1999;46:598–605
  87. Lawrence A, Jones CM, Wardman P, Burkitt MJ. Evidence for the role of a peroxidase compound I-type intermediate in the oxidation of glutathione, NADH, ascorbate, and dichlorofluorescin by cytochrome c/H2O2. Implications for oxidative stress during apoptosis. J. Biol. Chem. 2003;278:29410–29419
  88. LeBlanc AC. The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death. Curr. Alzheimer Res. 2005;2:389–402
  89. Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science. 2000;288:335–339
  90. Linton MF, Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. Curr. Opin. Pharmacol. 2004;4:116–123
  91. Liu H, Wang H, Shenvi S, Hagen TM, Liu RM. Glutathione metabolism during aging and in Alzheimer's disease. Ann. N Y Acad. Sci. 2004;1019:346–349
  92. Lymar SV, Jiang Q, Hurst JK. Mechanism of carbon dioxide-catalyzed oxidation of tyrosine by peroxynitrite. Biochemistry. 1996;35:7855–7861
  93. Maihöfner C, Probst-Cousin S, Bergmann M, Neuhuber W, Neundörfer B, Heuss D. Expression and localization of cyclooxygenase-1 and -2 in human sporadic amyotrophic lateral sclerosis. Eur. J. Neurosci. 2003;18:1527–1534
  94. Manfredi G, Xu Z. Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion. 2005;5:77–87
  95. Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkendam MA. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature. 1984;311:464–467
  96. McFaul SJ, Everse J. Continuous assay for cytolytic activity. In:  Di Sabato G,  Everse J editor. Immunochemical Techniques. Part J. Phagocytosis and Cell-Mediated Cytotoxicity (Methods in Enzymology). vol. 132:San Diego: Academic Press; 1986;p. 491–498
  97. McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve. 2002;26:459–470
  98. McGeer PL, McGeer EG. NSAIDs and Alzheimer's disease: epidemiological, animal model and clinical studies. Neurobiol. Aging. 2007;28:639–647
  99. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988;38:1285–1291
  100. McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE. Inositol stereoisomers stabilize oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J. Biol. Chem. 2000;275:18495–18502
  101. McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 2004;56:149–162
  102. McNaught KS, Olanow CW. Proteasome inhibitor-induced model of Parkinson's disease. Ann. Neurol. 2006;60:243–247
  103. Mitsumoto Y, Watanabe A, Mori A, Koga N. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem. Biophys. Res. Commun. 1998;248:660–663
  104. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol. 2004;63:901–910
  105. Nagano S, Huang X, Moir RD, Payton SM, Tanzi RE, Bush AI. Peroxidase activity of cyclooxygenase-2 (COX-2) cross-links β-amyloid (Aβ) and generates Aβ-COX-2 hetero-oligomers that are increased in Alzheimer's disease. J. Biol. Chem. 2004;279:14673–14678
  106. Nathan C, Calingasan N, Nezezon J, Ding A, Lucia MS, La Perle K, et al. J. Exp. Med. 2005;202:1163–1169
  107. Nishiyama K, Murayama S, Shimizu J, Ohya Y, Kwak S, Asayama K, et al. Cu/Zn superoxide dismutase-like immunoreactivity is present in Lewy bodies from Parkinson disease: a light and electron microscopic immunocytochemical study. Acta Neuropathol. 1995;89:471–474
  108. Pennathur S, Jackson-Lewis V, Przedborski S, Heinecke JW. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J. Biol. Chem. 1999;274:34621–34628
  109. Perier C, Tieu K, Guegan C, Caspersen C, Jackson-Lewis V, Carelli V, et al. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc. Natl. Acad. Sci. U.S.A. 2005;102:19126–19131
  110. Perluigi M, Poon HF, Hensley K, Pierce WM, Klein JB, Calabrese V, et al. Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice—a model of familial amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2005;38:960–968
  111. Poon HF, Frasier M, Shreve N, Calabrese V, Wolozin B, Butterfield DA. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice—a model of familial Parkinson's disease. Neurobiol. Dis. 2005;18:492–498
  112. Poon HF, Hensley K, Thongboonkerd V, Merchant ML, Lynn BC, Pierce WM, et al. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice—a model of amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2005;39:453–462
  113. Qin W, Peng Y, Ksiezak-Reding H, Ho L, Stetka B, Lovati E, et al. Inhibition of cyclooxygenase as potential novel therapeutic strategy in N1411 presenilin-2 familial Alzheimer's disease. Mol. Psychiatry. 2006;11:172–181
  114. Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc. Natl. Acad. Sci. U.S.A. 2004;101:4003–4008
  115. Reynolds MR, Berry RW, Binder LI. Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer's disease. Biochemistry. 2005;44:1690–1700
  116. Ristimaki A. Cyclooxygenase-2: from inflammation to carcinogenesis. Novartis Found Symp. 2004;256:215–221
  117. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 2003;60:1685–1991
  118. Sargsyan SA, Monk PN, Shaw PJ. Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia. 2005;51:241–253
  119. Sathasivam S, Grierson AJ, Shaw PJ. Characterization of the caspase cascade in a cell culture model of SOD1-related familial amyotrophic lateral sclerosis: expression, activation and therapeutic effects of inhibition. Neuropathol. Appl. Neurobiol. 2005;31:467–485
  120. Sawada H, Kohno R, Kihara T, Izumi Y, Sakka N, Ibi M, et al. Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions. J. Biol. Chem. 2004;279:10710–10719
  121. Sayre LM, Perry G, Atwood CS, Smith MA. The role of metals in neurodegenerative diseases. Cell Mol. Biol. 2000;46:731–741
  122. Schiess M. Non-steroidal anti-inflammatory drugs protect against Parkinson neurodegeneration. Arch. Neurol. 2003;60:1043–1044
  123. Schopfer FJ, Baker PR, Freeman BA. NO-dependent protein nitration: a cell signaling event or an oxidative inflammatory response?. Trends Biochem. Sci. 2003;28:646–654
  124. Schulz JB, Matthews RT, Klockgether T, Dichgans J, Beal MF. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol. Cell Biochem. 1997;174:193–197
  125. Shults CW. Lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 2006;103:1661–1668
  126. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 1994;36:348–355
  127. Simmons DL, Botting RM, Hla T. Cyclooxygenase isoenzymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 2004;56:387–437
  128. Smith MA, Richie Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 1997;17:2653–2657
  129. Smith DP, Ciccotosto GD, Tew DJ, Fodero-Tavoletti MT, Johanssen T, Masters CL, et al. Concentration dependent Cu2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide. Biochemistry. 2007;46:2881–2891
  130. Sonsalla PK, Heikkila RE. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur. J. Pharmacol. 1986;129:339–345
  131. Sriram K, Pai KS, Boyd MR, Ravindranath V. Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice. Brain Res. 1997;749:44–52
  132. Strausak D, Mercer JF, Dieter HH, Stremmel W, Multhaup G. Copper in disorders with neurological symptoms: Alzheimer's, Menkes, and Wilson diseases. Brain Res. Bull. 2001;55:175–185
  133. Strong MJ, Kesavapany S, Pant HC. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy?. J. Neuropathol. Exp. Neurol. 2005;64:649–664
  134. Tamagno E, Parola M, Guglielmotto M, Santoro G, Bardini P, Marra L, et al. Multiple signaling events in amyloid beta-induced, oxidative stress-dependent neuronal apoptosis. Free Radic. Biol. Med. 2003;35:45–58
  135. Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse. 2001;39:167–174
  136. Teismann P, Tieu K, Choi D-K, Wu D-C, Naini A, Hunot S, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 2003;100:5473–5478
  137. Teismann P, Vila M, Choi D-K, Tieu K, Wu D-C, Jackson-Lewis V, et al. COX-2 and neurodegeneration in Parkinson's disease. Ann. N Y Acad. Sci. 2003;991:272–277
  138. Tieu K, Ischiropoulos H, Przedborski S. Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB Life. 2003;55:329–335
  139. Trieu VN, Liu R, Liu XP, Uckun FM. A specific inhibitor of janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2000;267:22–25
  140. Valderrama B, Avala M, Vazquez-Duhalt R. Suicide inactivation of peroxidases and the challenge of engineering more robust enzymes. Chem. Biol. 2002;9:555–565
  141. Van den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocyclin delaysdisease onset and mortality in a transgenic mouse model of ALS. Neuroreport. 2002;13:1067–1070
  142. Vlasova II, Tyurin VA, Kapralov AA, Kurnikov IV, Osipov AN, Potapovich MV, et al. Nitric oxide inhibits peroxidase activity of cytochrome c.cardiolipin complex and blocks cardiolipin oxidation. J. Biol. Chem. 2006;281:14554–14562
  143. Wang T, Pei Z, Zhang W, Liu B, Langenbach R, Lee C, et al. MPP+-induced COX-2 activation and subsquent dopaminergic neurodegeneration. FASEB J. 2005;19:1134–1136
  144. Webster B, Hansen L, Adame A, Crews L, Torrance M, Thal L, et al. Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. J. Neuropathol. Exp. Neurol. 2006;65:142–151
  145. Wiedau-Pazos M, Goto JJ, Rabizadeh S, Gralla EB, Roe JA, Lee MK, et al. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science. 1996;271:515–518
  146. Wilkinson BL, Landreth GE. The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. Neuroinflammation. 2006;3:30
  147. Woodhouse A, Vickers JC, Dickson TC. Cytoplasmic cytochrome c immunolabelling in dystrophic neurites in Alzheimer's disease. Acta Neuropathol. 2006;112:429–437
  148. Wu RM, Chen RC, Chiueh CC. Effect of MAO-B inhibitors on MPP+ toxicity in vivo. Ann. N Y Acad. Sci. 2000;899:255–261
  149. Xu Z, Jung C, Higgins C, Levine J, Kong J. Mitochondrial degeneration in amyotrophic lateral sclerosis. J. Bioenerg. Biomembr. 2004;36:395–399
  150. Yim MB, Kang J-H, Yim H-S, Kwak H-S, Chock PB, Stadtman ER. A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: an enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proc. Natl. Acad. Sci. 1996;93:5709–5714
  151. Yim HS, Kang JH, Chock PB, Stadtman ER, Yim MB. A familial amyotrophic lateral sclerosis-associated A4V Cu,Zn-superoxide dismutase mutant has a lower Km for hydrogen peroxide. Correlation between clinical severity and the Km value. J. Biol. Chem. 1997;272:8861–8863
  152. Yim MB, Yim HS, Chock PB, Stadtman ER. Enhanced free radical generation of FALS-associated Cu,Zn-SOD mutants. Neurotox. Res. 1999;1:91–97
  153. Youdim MBH, Grünblatt E, Mandel S. The pivotal role of iron in NF-κB activation and nigrostriatal dopaminergic neurodegeneration. Ann. N Y Acad. Sci. 1999;890:7–25
  154. Zhang H, Joseph J, Gurney M, Becker D, Kalyanaraman B. Bicarbonate enhances peroxidase activity of Cu,Zn-superoxide dismutase. Role of carbonate anion radical and scavenging of carbonate anion radical by metalloporphyrin antioxidant enzyme mimetics. J. Biol. Chem. 2002;277:1013–1020
  155. Zhang H, Andrekopoulos C, Joseph J, Chandran K, Karoui H, Crow JP, et al. Bicarbonate-dependent peroxidase activity of human Cu,Zn-superoxide dismutase induces covalent aggregation of protein: intermediacy of tryptophan-derived oxidation products. J. Biol. Chem. 2003;278:24078–24089
  156. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005;19:533–542
  157. Zhou Y, Wang Y, Kovacs M, Zhang J. Microglial activation induced by neurodegeneration: a proteomic analysis. Mol. Cell Proteomics. 2005;4:1471–1479
  158. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002;417:74–78
  159. Zhu X, Smith MA, Perry G, Aliev G. Mitochondrial failures in Alzheimer's disease. Am. J. Alzheimers Dis. Other Dem. 2004;19:345–352
  160. Zhu X, Lee H, Moreira PI, Smith MA, Perry G. Presenilin mutation: a deadly first hit in Alzheimer disease. Free Radic. Biol. Med. 2006;40:737–739
  161. Zielasek J, Tausch M, Toyka KV, Hartung HP. Production of nitrite by neonatal rat microglial cells/brain macrophages. Cell Immunol. 1992;141:111–120
  162. Zuddas A, Corsini GU, Schinelli S, Barker JL, Kopin IJ, Di Porzio U. Acetaldehyde directly enhances MPP+ neurotoxicity and delays its elimination from the striatum. Brain Res. 1989;501:11–22

PII: S0197-4580(07)00409-5

doi: 10.1016/j.neurobiolaging.2007.10.007

Neurobiology of Aging
Volume 30, Issue 7 , Pages 1011-1025 , July 2009

Article Tools

* Image Usage & Resolution